ALK and lung cancer: Brigatinib (Fig. 1A) has been approved for treating ALK-positive metastatic non–small cell lung cancer that has deteriorated after crizotinib treatment or is intolerant to crizotinib in 2017 as for the first-line treatment of ALK-positive metastatic non–small cell lung cancer in 2020.